Nuveen
VTGN icon

Nuveen’s VistaGen Therapeutics VTGN Stock Holding History

Nuveen’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,587
Closed -$597K – 3141
2022
Q4 		$597K Sell
18,587
-1,136
-6% -$4.28K ﹤0.01% 2836
2022
Q3 		$633K Sell
19,723
-66
-0.3% -$654 ﹤0.01% 2901
2022
Q2 		$523K Sell
19,789
-521
-3% -$18.4K ﹤0.01% 3005
2022
Q1 		$719K Buy
20,310
+275
+1% +$12K ﹤0.01% 2917
2021
Q4 		$1.05M Sell
20,035
-1,944
-9% -$127K ﹤0.01% 2848
2021
Q3 		$1.97M Sell
21,979
-900
-4% -$78.2K ﹤0.01% 2676
2021
Q2 		$2.16M Buy
+22,879
New +$1.7M ﹤0.01% 2673

Other funds holding VTGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's VTGN Position: Q1 2023 in Review

Nuveen sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 18,587 shares — an estimated $597K sold.

Nuveen first reported a position in VTGN in Q2 2021 and held it in 7 quarters. The position peaked at $2.16M in Q2 2021. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Nuveen reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Nuveen sold 18,587 VistaGen Therapeutics shares in Q1 2023, an estimated $597K.
  • Nuveen first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 7 quarters.
  • Nuveen's VistaGen Therapeutics position peaked at $2.16M in Q2 2021.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Nuveen's 13F filing for Q1 2023, filed 15 May 2023.